Revolutionary cone replacement therapy for central vision loss
OkuloVision is dedicated to the prevention and treatment of blinding diseases using our breakthrough first-in-man Cone Progenitor Cell (CPC) therapies.
Over 15 million adults in the U.S. and Europe alone suffer from Inherited Retinal Diseases and Age-Related Macular Degeneration, with no viable option to replace or regenerate deteriorated cone cells, thus reversing the process of complete central vision loss.
The scientific community is faced with an urgent opportunity to rise to the occasion and develop therapeutic solutions for this staggering unmet need.
CPCs offer a promising future for patients and are commercially viable. They can be manufactured at scale, show unprecedented retinal integration efficiency, and improve visual function.
We’ve gathered some of the brightest minds in regenerative medicine and ophthalmology to collaborate together on this shared mission to improve quality of life through Better Vision for All.
While CPC therapies are in development, we remain dedicated to being a trusted source of educational information for patients with central vision loss and their caretakers.